carbidopa, levodopa drug combination has been researched along with Disease Models, Animal in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
| Ashby, R; Karouta, C; Kelly, T; Morgan, I; Thomson, K | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Alhadhrami, A; Alharthi, SS; Alrobaian, MM; Kabel, AM; Omar, MS | 1 |
| Ikram, R; Riaz, B; Sikandar, B | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Gash, DM; Kim, MH; Kurlan, R | 1 |
| Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 1 |
1 review(s) available for carbidopa, levodopa drug combination and Disease Models, Animal
| Article | Year |
|---|---|
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
12 other study(ies) available for carbidopa, levodopa drug combination and Disease Models, Animal
| Article | Year |
|---|---|
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens.
Topics: Administration, Topical; Animals; Animals, Newborn; Biomarkers; Carbidopa; Chickens; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Injections, Intraperitoneal; Levodopa; Male; Mitosis; Myopia; Ophthalmic Solutions; Sensory Deprivation; Vitreous Body | 2021 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2018 |
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hydrogen-Ion Concentration; Levodopa; Parkinsonian Disorders; Rats; Water | 2018 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior | 1991 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |